<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03828292</url>
  </required_header>
  <id_info>
    <org_study_id>207504</org_study_id>
    <nct_id>NCT03828292</nct_id>
  </id_info>
  <brief_title>An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments</brief_title>
  <official_title>A Phase I Open-Label, Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of the Antibody Drug Conjugate GSK2857916 in Japanese Participants With Relapsed/Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Belantamab mafodotin (GSK2857916) is a first in class, antibody dependent cellular&#xD;
      cytotoxicity (ADCC) enhanced, humanized immunoglobulin G1 (IgG1) antibody-drug conjugate&#xD;
      (ADC) which binds specifically to B cell maturation antigen (BCMA) expressed on tumor cells&#xD;
      of all participants with multiple myeloma. This is a Phase 1, open label, dose escalation&#xD;
      study to investigate safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity&#xD;
      and clinical activity of GSK2857916 when given as monotherapy (Part 1) or given as&#xD;
      combination therapy (Part 2). Dose escalation will follow a 3+3 design.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 14, 2019</start_date>
  <completion_date type="Anticipated">June 9, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 9, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Participants will receive GSK2857916 monotherapy during Part 1 (Dose escalation) of the study on a once every 21 days schedule. During Part 2, participants will receive GSK2857916 given in combination with Bortezomib/Dexamethasone on a once every 21 days schedule (Arm A) or with Pomalidomide/Dexamethasone on a once every 28 days schedule (Arm B).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>This will be an open-label study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Number of participants with dose limiting toxicities (DLTs)</measure>
    <time_frame>Day 1 to 21 of Cycle 1 (each cycle of 21 days)</time_frame>
    <description>The number of participants with DLTs will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Arm A: Number of participants with DLTs</measure>
    <time_frame>Day 1 to 21 of Cycle 1 (each cycle of 21 days)</time_frame>
    <description>The number of participants with DLTs will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Arm B: Number of participants with DLTs</measure>
    <time_frame>Day 1 to 28 of Cycle 1 (each cycle of 28 days)</time_frame>
    <description>The number of participants with DLTs will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 and Part 2: Number of participants with adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>Up to approximately 2.2 years</time_frame>
    <description>AEs and SAEs will be collected.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 and Part 2: Number of participants with abnormal hematology, clinical chemistry, urinalysis parameters</measure>
    <time_frame>Up to approximately 2.2 years</time_frame>
    <description>Blood and urine samples will be collected for the assessment of hematology, clinical chemistry and urinalysis parameters.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 and Part 2: Number of participants with abnormal vital signs</measure>
    <time_frame>Up to approximately 2.2 years</time_frame>
    <description>Number of participants with abnormal vital signs will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 and Part 2: Number of participants with abnormal electrocardiogram (ECG) findings</measure>
    <time_frame>Up to approximately 2.2 years</time_frame>
    <description>A 12-lead ECG will be obtained using an ECG machine. Number of participants with abnormal ECG parameters will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 and Part 2: Number of participants with abnormal physical examination findings</measure>
    <time_frame>Up to approximately 2.2 years</time_frame>
    <description>Number of participants with abnormal findings in physical examination will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 and Part 2: Number of participants with abnormal ocular examination findings</measure>
    <time_frame>Up to approximately 2.2 years</time_frame>
    <description>Number of participants with abnormal ocular examination findings will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 and Part 2: Mean Eastern Cooperative Oncology Group (ECOG) scores</measure>
    <time_frame>Up to approximately 2.2 years</time_frame>
    <description>The performance status of participants will be assessed using the ECOG Scale ranging from 0 (normal activity) to 5 (Dead).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: Area under the plasma concentration time curve from time 0 to the time of the last quantifiable concentration (AUC [0 to t]) for GSK2857916 following single dose administration</measure>
    <time_frame>Cycle1 Day1 (pre-dose, end of infusion, 1, 3, 8, 24 hours post-infusion), Day8, Day15 (21-day cycle)</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Arm A: AUC (0 to t) for GSK2857916 following single dose administration</measure>
    <time_frame>Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (21-day cycle)</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Arm B: AUC (0 to t) for GSK2857916 following single dose administration</measure>
    <time_frame>Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (28-day cycle)</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Area under the plasma concentration-time curve from time 0 to the end of dosing (AUC [0 to tau]) for GSK2857916 following single dose administration</measure>
    <time_frame>Cycle1 Day1 (pre-dose, end of infusion, 1, 3, 8, 24 hours post-infusion), Day8, Day15 (21-day cycle)</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Arm A: AUC (0 to tau) for GSK2857916 following single dose administration</measure>
    <time_frame>Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (21-day cycle)</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Arm B: AUC (0 to tau) for GSK2857916 following single dose administration</measure>
    <time_frame>Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (28-day cycle)</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Area under the plasma concentration-time curve from time 0 to infinite time (AUC [0 to inf]) for GSK2857916 following single dose administration</measure>
    <time_frame>Cycle1 Day1 (pre-dose, end of infusion, 1, 3, 8, 24 hours post-infusion), Day8, Day15 (21-day cycle)</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Arm A: AUC (0 to inf) for GSK2857916 following single dose administration</measure>
    <time_frame>Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (21-day cycle)</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Arm B: AUC (0 to inf) for GSK2857916 following single dose administration</measure>
    <time_frame>Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (28-day cycle)</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Maximum observed plasma concentration (Cmax) for GSK2857916 following single dose administration</measure>
    <time_frame>Cycle1 Day1 (pre-dose, end of infusion, 1, 3, 8, 24 hours post-infusion), Day8, Day15 (21-day cycle)</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Arm A: Cmax for GSK2857916 following single dose administration</measure>
    <time_frame>Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (21-day cycle)</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Arm B: Cmax for GSK2857916 following single dose administration</measure>
    <time_frame>Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (28-day cycle)</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Time to Cmax (Tmax) for GSK2857916 following single dose administration</measure>
    <time_frame>Cycle1 Day1 (pre-dose, end of infusion, 1, 3, 8, 24 hours post-infusion), Day8, Day15 (21-day cycle)</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Arm A: Tmax for GSK2857916 following single dose administration</measure>
    <time_frame>Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (21-day cycle)</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Arm B: Tmax for GSK2857916 following single dose administration</measure>
    <time_frame>Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (28-day cycle)</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Systemic clearance (CL) for GSK2857916 following single dose administration</measure>
    <time_frame>Cycle1 Day1 (pre-dose, end of infusion, 1, 3, 8, 24 hours post-infusion), Day8, Day15 (21-day cycle)</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Arm A: CL for GSK2857916 following single dose administration</measure>
    <time_frame>Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (21-day cycle)</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Arm B: CL for GSK2857916 following single dose administration</measure>
    <time_frame>Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (28-day cycle)</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Volume of distribution at steady state (Vss) for GSK2857916 following single dose administration</measure>
    <time_frame>Cycle1 Day1 (pre-dose, end of infusion, 1, 3, 8, 24 hours post-infusion), Day8, Day15 (21-day cycle)</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Arm A: Vss for GSK2857916 following single dose administration</measure>
    <time_frame>Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (21-day cycle)</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Arm B: Vss for GSK2857916 following single dose administration</measure>
    <time_frame>Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (28-day cycle)</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Terminal phase half-life (T1/2) for GSK2857916 following single dose administration</measure>
    <time_frame>Cycle1 Day1 (pre-dose, end of infusion, 1, 3, 8, 24 hours post-infusion), Day8, Day15 (21-day cycle)</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Arm A: T1/2 for GSK2857916 following single dose administration</measure>
    <time_frame>Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (21-day cycle)</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Arm B: T1/2 for GSK2857916 following single dose administration</measure>
    <time_frame>Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (28-day cycle)</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Concentration at the end of infusion of GSK2857916 following repeat dose administration</measure>
    <time_frame>Cycle1 Day1 (pre-dose, end of infusion, 1, 3, 8, 24 hours post-infusion), Day8, Day15; Cycle 2 Day1, Cycle 3 Day1, Cycle 6 Day1, Cycle9 Day1, and Cycle12 Day1 (pre-dose, end of infusion); Cycle 16 Day1 (pre-dose) (21-day cycle)</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Arm A: Concentration at the end of infusion of GSK2857916 following repeat dose administration</measure>
    <time_frame>Up to approximately 2.2 years</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Arm B: Concentration at the end of infusion of GSK2857916 following repeat dose administration</measure>
    <time_frame>Up to approximately 2.2 years</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Trough plasma concentration (Ctrough) for GSK2857916 following repeat dose administration</measure>
    <time_frame>Cycle1 Day1 (pre-dose, end of infusion, 1, 3, 8, 24 hours post-infusion), Day8, Day15; Cycle 2 Day1, Cycle 3 Day1, Cycle 6 Day1, Cycle9 Day1, and Cycle12 Day1 (pre-dose, end of infusion); Cycle 16 Day1 (pre-dose) (21-day cycle)</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Arm A: Ctrough for GSK2857916 following repeat dose administration</measure>
    <time_frame>Up to approximately 2.2 years</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Arm B: Ctrough for GSK2857916 following repeat dose administration</measure>
    <time_frame>Up to approximately 2.2 years</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Observed accumulation ratio for GSK2857916 following repeat dose administration</measure>
    <time_frame>Cycle1 Day1 (pre-dose, end of infusion, 1, 3, 8, 24 hours post-infusion), Day8, Day15; Cycle 2 Day1, Cycle 3 Day1, Cycle 6 Day1, Cycle9 Day1, and Cycle12 Day1 (pre-dose, end of infusion); Cycle 16 Day1 (pre-dose) (21-day cycle)</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Arm A: Observed accumulation ratio for GSK2857916 following repeat dose administration</measure>
    <time_frame>Up to approximately 2.2 years</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Arm B: Observed accumulation ratio for GSK2857916 following repeat dose administration</measure>
    <time_frame>Up to approximately 2.2 years</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: AUC (0 to t) for Cysteine maleimidocaproyl monomethyl auristatin F (cys-mcMMAF) following single dose administration</measure>
    <time_frame>Cycle1 Day1 (pre-dose, end of infusion, 1, 3, 8, 24 hours post-infusion), Day8, Day15 (21-day cycle)</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Arm A: AUC (0 to t) for cys-mcMMAF following single dose administration</measure>
    <time_frame>Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (21-day cycle)</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Arm B: AUC (0 to t) for cys-mcMMAF following single dose administration</measure>
    <time_frame>Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (28-day cycle)</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: AUC (0 to tau) for cys-mcMMAF following single dose administration</measure>
    <time_frame>Cycle1 Day1 (pre-dose, end of infusion, 1, 3, 8, 24 hours post-infusion), Day8, Day15 (21-day cycle)</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Arm A: AUC (0 to tau) for cys-mcMMAF following single dose administration</measure>
    <time_frame>Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (21-day cycle)</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Arm B: AUC (0 to tau) for cys-mcMMAF following single dose administration</measure>
    <time_frame>Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (28-day cycle)</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: AUC (0 to inf) for cys-mcMMAF following single dose administration</measure>
    <time_frame>Cycle1 Day1 (pre-dose, end of infusion, 1, 3, 8, 24 hours post-infusion), Day8, Day15 (21-day cycle)</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Arm A: AUC (0 to inf) for cys-mcMMAF following single dose administration</measure>
    <time_frame>Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (21-day cycle)</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Arm B: AUC (0 to inf) for cys-mcMMAF following single dose administration</measure>
    <time_frame>Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (28-day cycle)</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Cmax for cys-mcMMAF following single dose administration</measure>
    <time_frame>Cycle1 Day1 (pre-dose, end of infusion, 1, 3, 8, 24 hours post-infusion), Day8, Day15 (21-day cycle)</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Arm A: Cmax for cys-mcMMAF following single dose administration</measure>
    <time_frame>Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (21-day cycle)</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Arm B: Cmax for cys-mcMMAF following single dose administration</measure>
    <time_frame>Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (28-day cycle)</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Tmax for cys-mcMMAF following single dose administration</measure>
    <time_frame>Cycle1 Day1 (pre-dose, end of infusion, 1, 3, 8, 24 hours post-infusion), Day8, Day15 (21-day cycle)</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Arm A: Tmax for cys-mcMMAF following single dose administration</measure>
    <time_frame>Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (21-day cycle)</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Arm B: Tmax for cys-mcMMAF following single dose administration</measure>
    <time_frame>Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (28-day cycle)</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: T1/2 for cys-mcMMAF following single dose administration</measure>
    <time_frame>Cycle1 Day1 (pre-dose, end of infusion, 1, 3, 8, 24 hours post-infusion), Day8, Day15 (21-day cycle)</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Arm A: T1/2 for cys-mcMMAF following single dose administration</measure>
    <time_frame>Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (21-day cycle)</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Arm B: T1/2 for cys-mcMMAF following single dose administration</measure>
    <time_frame>Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (28-day cycle)</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Concentration at end of infusion for cys-mcMMAF following repeat dose administration</measure>
    <time_frame>Cycle1 Day1 (pre-dose, end of infusion, 1, 3, 8, 24 hours post-infusion), Day8, Day15; Cycle 2 Day1, Cycle 3 Day1, Cycle 6 Day1, Cycle9 Day1, and Cycle12 Day1 (pre-dose, end of infusion); Cycle 16 Day1 (pre-dose) (21-day cycle)</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Arm A: Concentration at end of infusion for cys-mcMMAF following repeat dose administration</measure>
    <time_frame>Up to approximately 2.2 years</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Arm B: Concentration at end of infusion for cys-mcMMAF following repeat dose administration</measure>
    <time_frame>Up to approximately 2.2 years</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Ctrough for cys-mcMMAF following repeat dose administration</measure>
    <time_frame>Cycle1 Day1 (pre-dose, end of infusion, 1, 3, 8, 24 hours post-infusion), Day8, Day15; Cycle 2 Day1, Cycle 3 Day1, Cycle 6 Day1, Cycle9 Day1, and Cycle12 Day1 (pre-dose, end of infusion); Cycle 16 Day1 (pre-dose) (21-day cycle)</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Arm A: Ctrough for cys-mcMMAF following repeat dose administration</measure>
    <time_frame>Up to approximately 2.2 years</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Arm B: Ctrough for cys-mcMMAF following repeat dose administration</measure>
    <time_frame>Up to approximately 2.2 years</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Observed accumulation ratio for cys-mcMMAF following repeat dose administration</measure>
    <time_frame>Cycle1 Day1 (pre-dose, end of infusion, 1, 3, 8, 24 hours post-infusion), Day8, Day15; Cycle 2 Day1, Cycle 3 Day1, Cycle 6 Day1, Cycle9 Day1, and Cycle12 Day1 (pre-dose, end of infusion); Cycle 16 Day1 (pre-dose) (21-day cycle)</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Arm A: Observed accumulation ratio for cys-mcMMAF following repeat dose administration</measure>
    <time_frame>Up to approximately 2.2 years</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Arm B: Observed accumulation ratio for cys-mcMMAF following repeat dose administration</measure>
    <time_frame>Up to approximately 2.2 years</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2: Number of participants who develop anti-drug antibodies (ADAs) against GSK2857916</measure>
    <time_frame>Up to approximately 2.2 years</time_frame>
    <description>Serum samples will be collected for analysis of presence of anti-GSK2857916 antibodies by a validated electrochemiluminescent immunoassay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2: Titers of anti-GSK2857916 antibodies</measure>
    <time_frame>Up to approximately 2.2 years</time_frame>
    <description>Serum samples will be collected for analysis of presence of anti-GSK2857916 antibodies by a validated electrochemiluminescent immunoassay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2: Overall response rate</measure>
    <time_frame>Up to approximately 2.2 years</time_frame>
    <description>Overall response rate is defined as the percentage of participants with a confirmed partial response or better, according to the International Myeloma Working Group (IMWG) response criteria, as assessed by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2: Clinical benefit rate</measure>
    <time_frame>Up to approximately 2.2 years</time_frame>
    <description>Clinical benefit rate is defined as the percentage of participants with a confirmed minimal response (MR) or better, according to the IMWG response criteria, as assessed by the investigator.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Part 1: Belantamab mafodotin Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Arm A: Belantamab mafodotin+Bortezomib/Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Arm B: Belantamab mafodotin+Pomalidomide/Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belantamab mafodotin</intervention_name>
    <description>Belantamab mafodotin will be administered as an intravenous infusion.</description>
    <arm_group_label>Part 1: Belantamab mafodotin Monotherapy</arm_group_label>
    <arm_group_label>Part 2: Arm A: Belantamab mafodotin+Bortezomib/Dexamethasone</arm_group_label>
    <arm_group_label>Part 2: Arm B: Belantamab mafodotin+Pomalidomide/Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Bortezomib solution for injection will be administered subcutaneously.</description>
    <arm_group_label>Part 2: Arm A: Belantamab mafodotin+Bortezomib/Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone tablets will be administered orally.</description>
    <arm_group_label>Part 2: Arm A: Belantamab mafodotin+Bortezomib/Dexamethasone</arm_group_label>
    <arm_group_label>Part 2: Arm B: Belantamab mafodotin+Pomalidomide/Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide</intervention_name>
    <description>Pomalidomide capsules will be administered orally.</description>
    <arm_group_label>Part 2: Arm B: Belantamab mafodotin+Pomalidomide/Dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Provide signed written informed consent, which includes compliance with the&#xD;
             requirements and restrictions listed in the consent form.&#xD;
&#xD;
          -  Male or female, 20 years or older (at the time consent is obtained).&#xD;
&#xD;
          -  ECOG performance status of 0 to 2.&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of multiple myeloma as defined&#xD;
             according to IMWG 2014, criteria in a participant who fulfills all of the following:&#xD;
             has undergone stem cell transplant, or is considered transplant ineligible, Part 1:&#xD;
             has received at least 2 prior lines of anti-myeloma drugs containing at least 1&#xD;
             proteasome inhibitor and at least 1 immunomodulator, Part 2: has received at least 1&#xD;
             prior line of anti-myeloma drugs; has demonstrated progression on, or within 60 days&#xD;
             of completion of the last therapy.&#xD;
&#xD;
          -  Has measurable disease with at least one of the following: serum M-protein &gt;=0.5 grams&#xD;
             per deciliter (g/dL) (&gt;=5 grams per liter [g/L]); Urine M-protein &gt;=200 mg/24 hours;&#xD;
             Serum free light chain (FLC) assay: Involved FLC level &gt;=10 mg/dL (&gt;=100 mg/L) and an&#xD;
             abnormal serum FLC ratio (&lt;0.26 or &gt;1.65).&#xD;
&#xD;
          -  Participants with a history of autologous stem cell transplant are eligible for study&#xD;
             participation provided the following eligibility criteria are met: Transplant was &gt;100&#xD;
             days prior to study enrolment; No active infection.&#xD;
&#xD;
          -  Female participants: Contraceptive use by women should be consistent with local&#xD;
             regulations regarding the methods of contraception for those participating in clinical&#xD;
             studies. A female participant is eligible to participate if she is not pregnant or&#xD;
             breast feeding, and at least one of the following conditions applies: Is not a woman&#xD;
             of childbearing potential (WOCBP) or For Part 1 and Part 2 Arm A: Is a WOCBP and using&#xD;
             a contraceptive method that is highly effective (with a failure rate of &lt;1 percent per&#xD;
             year), preferably with low user dependency, during the treatment period and for 4&#xD;
             months after the last dose of GSK2857916, and 7 months from the last dose of&#xD;
             bortezomib (only Part 2 Arm A), and agrees not to donate eggs (ova, oocytes) for the&#xD;
             purpose of reproduction during this period. The investigator should evaluate the&#xD;
             effectiveness of the contraceptive method in relationship to the first dose of study&#xD;
             treatment. A WOCBP must have a negative highly sensitive serum pregnancy test (as&#xD;
             required by local regulations) within 72 hours before the first dose of study&#xD;
             treatment and agree to use effective contraception during the study and for 4 months&#xD;
             after the last dose of GSK2857916, and 7 months from the last dose of bortezomib (only&#xD;
             Part 2 Arm A); For Part 2 Arm B: Due to pomalidomide being a thalidomide analogue with&#xD;
             risk for embryo-fetal toxicity and prescribed under a restricted distribution program,&#xD;
             WOCBP participants will be eligible if they commit either to abstain continuously from&#xD;
             heterosexual sexual intercourse or to use 2 methods of reliable birth control,&#xD;
             beginning 4 weeks prior to initiating treatment with pomalidomide, during therapy,&#xD;
             during dose interruptions and continuing for 4 weeks following discontinuation of&#xD;
             pomalidomide treatment. Thereafter, WOCBP participants must use a contraceptive method&#xD;
             that is highly effective (with a failure rate of &lt;1 percent per year) for a further 3&#xD;
             months, and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction&#xD;
             during this period. Two negative pregnancy tests must be obtained prior to initiating&#xD;
             pomalidomide therapy. The first test should be performed within 10 to 14 days and the&#xD;
             second test within 24 hours prior to prescribing pomalidomide therapy. The&#xD;
             investigator is responsible for review of medical history, menstrual history, and&#xD;
             recent sexual activity to decrease the risk for inclusion of a woman with an early&#xD;
             undetected pregnancy.&#xD;
&#xD;
          -  Male participants: Contraceptive use by men should be consistent with local&#xD;
             regulations regarding the methods of contraception for those participating in clinical&#xD;
             studies. Male participants are eligible to participate if they agree to the following&#xD;
             from the time of first dose of study treatment until 6 months after the last dose of&#xD;
             GSK2857916, 4 months after the last dose of bortezomib (only Part 2 Arm A), and 4&#xD;
             weeks after the last dose of pomalidomide (only Part 2 Arm B) to allow for clearance&#xD;
             of any altered sperm: Refrain from donating sperm plus either: Be abstinent from&#xD;
             heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long&#xD;
             term and persistent basis) and agree to remain abstinent; or must agree to use&#xD;
             contraception/barrier as detailed: Agree to use a male condom even if they have&#xD;
             undergone a successful vasectomy and female partner to use an additional highly&#xD;
             effective contraceptive method with a failure rate of &lt;1 percent per year as when&#xD;
             having sexual intercourse with a woman of childbearing potential (including pregnant&#xD;
             females).&#xD;
&#xD;
          -  All prior treatment-related toxicities (defined by National Cancer Institute-Common&#xD;
             Toxicity Criteria for Adverse Events (NCI-CTCAE), version 4.03, must be &lt;=Grade 1 at&#xD;
             the time of enrolment except for alopecia. Participants with Grade 2 peripheral&#xD;
             neuropathy can be enrolled into Part 1 and Part 2 Arm B but not into Part 2 Arm A.&#xD;
&#xD;
          -  Adequate Organ System Function. Exclusion Criteria&#xD;
&#xD;
          -  Systemic anti-tumor-therapy within 14 days, or plasmapheresis within 7 days prior to&#xD;
             the first dose of study treatment.&#xD;
&#xD;
          -  Symptomatic amyloidosis, active 'polyneuropathy, organomegaly, endocrinopathy, myeloma&#xD;
             protein, and skin changes' (POEMS) syndrome, active plasma cell leukemia at the time&#xD;
             of screening.&#xD;
&#xD;
          -  Use of an investigational drug within 14 days or 5 half-lives, whichever is shorter,&#xD;
             preceding the first dose of study treatment. Prior treatment with a monoclonal&#xD;
             antibody within 30 days of receiving the first dose of study treatment. Prior BCMA&#xD;
             targeted therapy.&#xD;
&#xD;
          -  History of an allogeneic stem cell transplant.&#xD;
&#xD;
          -  Current use of prohibited medications/device or planned use of any of these during the&#xD;
             study period.&#xD;
&#xD;
          -  Current corneal epithelial disease except mild punctate keratopathy&#xD;
&#xD;
          -  Presence of active renal condition (infection, requirement for dialysis or any other&#xD;
             condition that could affect participant's safety). Participants with isolated&#xD;
             proteinuria resulting from multiple myeloma are eligible, provided they fulfil the&#xD;
             required criteria.&#xD;
&#xD;
          -  Evidence of active mucosal or internal bleeding.&#xD;
&#xD;
          -  Any major surgery within the last 4 weeks.&#xD;
&#xD;
          -  Any serious and/or unstable pre-existing medical, psychiatric disorder, or other&#xD;
             conditions (including laboratory abnormalities) that could interfere with&#xD;
             participant's safety, obtaining informed consent or compliance to the study&#xD;
             procedures.&#xD;
&#xD;
          -  Active infection requiring treatment (antibiotic, antiviral, or antifungal treatment).&#xD;
&#xD;
          -  Evidence of severe or uncontrolled systemic diseases.&#xD;
&#xD;
          -  Malignancies other than disease under study are excluded, except for any other&#xD;
             malignancy from which the participant has been disease-free for more than 2 years and,&#xD;
             in the opinion of the investigators and Medical Monitor, will not affect the&#xD;
             evaluation of the effects of this clinical study treatment on the currently targeted&#xD;
             malignancy (multiple myeloma).&#xD;
&#xD;
          -  Evidence of cardiovascular risk including any of the following:&#xD;
&#xD;
               1. Corrected QT interval Fridericia (QTcF) interval &gt;=470 milliseconds (msecs) (the&#xD;
                  QT interval values must be corrected for heart rate by Fridericia's formula&#xD;
                  [QTcF])&#xD;
&#xD;
               2. Evidence of current clinically significant uncontrolled arrhythmias, including&#xD;
                  clinically significant ECG abnormalities such as 2nd degree (Type II) or 3rd&#xD;
                  degree atrioventricular (AV) block.&#xD;
&#xD;
               3. History of myocardial infarction, acute coronary syndromes (including unstable&#xD;
                  angina), coronary angioplasty, or stenting or bypass grafting within 6 months of&#xD;
                  Screening.&#xD;
&#xD;
               4. Class III or IV heart failure as defined by the New York Heart Association&#xD;
                  functional classification system&#xD;
&#xD;
               5. Uncontrolled hypertension&#xD;
&#xD;
          -  Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs&#xD;
             chemically related to GSK2857916 or any of the components of the study treatment.&#xD;
&#xD;
          -  Pregnant or lactating female or female who are interrupting lactation.&#xD;
&#xD;
          -  Known human Immunodeficiency virus (HIV) infection.&#xD;
&#xD;
          -  Presence of hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (HBsAb)&#xD;
             or hepatitis B core antibody (HBcAb at Screening or within 3 months prior to first&#xD;
             dose of study treatment).&#xD;
&#xD;
          -  Positive hepatitis C antibody test result or positive hepatitis C ribonucleic acid&#xD;
             (RNA) test result at screening or within 3 months prior to first dose of study&#xD;
             treatment. Participants with positive hepatitis C antibody due to prior resolved&#xD;
             disease can only be enrolled, if a confirmatory negative hepatitis C RNA test is&#xD;
             obtained. Hepatitis RNA testing is optional and participants with negative hepatitis C&#xD;
             antibody test are not required to also undergo hepatitis C RNA testing.&#xD;
&#xD;
          -  Current unstable liver or biliary disease per investigator assessment defined by the&#xD;
             presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or&#xD;
             gastric varices, persistent jaundice, or cirrhosis. Stable chronic liver disease&#xD;
             (including Gilbert's syndrome or asymptomatic gallstones) or hepatobiliary involvement&#xD;
             of malignancy is acceptable if participant otherwise meets entry criteria.&#xD;
&#xD;
          -  Previously diagnosed with interstitial lung disease or current complication of&#xD;
             interstitial lung disease.&#xD;
&#xD;
        Additional Exclusion Criteria for Part 2 Arm A&#xD;
&#xD;
          -  Intolerant to bortezomib or refractory to bortezomib.&#xD;
&#xD;
          -  Ongoing Grade 2 or higher peripheral neuropathy or neuropathic pain.&#xD;
&#xD;
          -  Intolerance or contraindications to herpes zoster prophylaxis Additional Exclusion&#xD;
             Criteria for Part 2 Arm B&#xD;
&#xD;
          -  Prior pomalidomide use.&#xD;
&#xD;
          -  Intolerance or contraindications to antithrombotic prophylaxis.&#xD;
&#xD;
          -  Active or history of venous thromboembolism within 3 months prior to first dose of&#xD;
             study treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aichi</city>
        <zip>467-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Okayama</city>
        <zip>701-1192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>150-8935</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2022</verification_date>
  <study_first_submitted>January 31, 2019</study_first_submitted>
  <study_first_submitted_qc>January 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2019</study_first_posted>
  <last_update_submitted>February 8, 2022</last_update_submitted>
  <last_update_submitted_qc>February 8, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antibody drug conjugate</keyword>
  <keyword>Dose-escalation</keyword>
  <keyword>GSK2857916</keyword>
  <keyword>Japanese</keyword>
  <keyword>Relapsed/Refractory Multiple Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03828292
org study id: 207504
nct id: NCT03828292
lead sponsor: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
Belantamab mafodotin (GSK2857916) is a first in class, antibody dependent cellular
      cytotoxicity (ADCC) enhanced, humanized immunoglobulin G1 (IgG1) antibody-drug conjugate
      (ADC) which binds specifically to B cell maturation antigen (BCMA) expressed on tumor cells
      of all participants with multiple myeloma. This is a Phase 1, open label, dose escalation
      study to investigate safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity
      and clinical activity of GSK2857916 when given as monotherapy (Part 1) or given as
      combination therapy (Part 2). Dose escalation will follow a 3+3 design.
allocation: Non-Randomized
intervention model: Sequential Assignment
intervention model description: Participants will receive GSK2857916 monotherapy during Part 1 (Dose escalation) of the study on a once every 21 days schedule. During Part 2, participants will receive GSK2857916 given in combination with Bortezomib/Dexamethasone on a once every 21 days schedule (Arm A) or with Pomalidomide/Dexamethasone on a once every 28 days schedule (Arm B).
primary purpose: Treatment
masking: None (Open Label)
masking description: This will be an open-label study.
measure: Part 1: Number of participants with dose limiting toxicities (DLTs)
time frame: Day 1 to 21 of Cycle 1 (each cycle of 21 days)
description: The number of participants with DLTs will be reported.
measure: Part 2: Arm A: Number of participants with DLTs
time frame: Day 1 to 21 of Cycle 1 (each cycle of 21 days)
description: The number of participants with DLTs will be reported.
measure: Part 2: Arm B: Number of participants with DLTs
time frame: Day 1 to 28 of Cycle 1 (each cycle of 28 days)
description: The number of participants with DLTs will be reported.
measure: Part 1 and Part 2: Number of participants with adverse events (AEs) and serious adverse events (SAEs)
time frame: Up to approximately 2.2 years
description: AEs and SAEs will be collected.
measure: Part 1 and Part 2: Number of participants with abnormal hematology, clinical chemistry, urinalysis parameters
time frame: Up to approximately 2.2 years
description: Blood and urine samples will be collected for the assessment of hematology, clinical chemistry and urinalysis parameters.
measure: Part 1 and Part 2: Number of participants with abnormal vital signs
time frame: Up to approximately 2.2 years
description: Number of participants with abnormal vital signs will be assessed.
measure: Part 1 and Part 2: Number of participants with abnormal electrocardiogram (ECG) findings
time frame: Up to approximately 2.2 years
description: A 12-lead ECG will be obtained using an ECG machine. Number of participants with abnormal ECG parameters will be assessed.
measure: Part 1 and Part 2: Number of participants with abnormal physical examination findings
time frame: Up to approximately 2.2 years
description: Number of participants with abnormal findings in physical examination will be assessed.
measure: Part 1 and Part 2: Number of participants with abnormal ocular examination findings
time frame: Up to approximately 2.2 years
description: Number of participants with abnormal ocular examination findings will be reported.
measure: Part 1 and Part 2: Mean Eastern Cooperative Oncology Group (ECOG) scores
time frame: Up to approximately 2.2 years
description: The performance status of participants will be assessed using the ECOG Scale ranging from 0 (normal activity) to 5 (Dead).
measure: Part 1: Area under the plasma concentration time curve from time 0 to the time of the last quantifiable concentration (AUC [0 to t]) for GSK2857916 following single dose administration
time frame: Cycle1 Day1 (pre-dose, end of infusion, 1, 3, 8, 24 hours post-infusion), Day8, Day15 (21-day cycle)
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.
measure: Part 2: Arm A: AUC (0 to t) for GSK2857916 following single dose administration
time frame: Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (21-day cycle)
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.
measure: Part 2: Arm B: AUC (0 to t) for GSK2857916 following single dose administration
time frame: Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (28-day cycle)
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.
measure: Part 1: Area under the plasma concentration-time curve from time 0 to the end of dosing (AUC [0 to tau]) for GSK2857916 following single dose administration
time frame: Cycle1 Day1 (pre-dose, end of infusion, 1, 3, 8, 24 hours post-infusion), Day8, Day15 (21-day cycle)
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.
measure: Part 2: Arm A: AUC (0 to tau) for GSK2857916 following single dose administration
time frame: Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (21-day cycle)
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.
measure: Part 2: Arm B: AUC (0 to tau) for GSK2857916 following single dose administration
time frame: Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (28-day cycle)
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.
measure: Part 1: Area under the plasma concentration-time curve from time 0 to infinite time (AUC [0 to inf]) for GSK2857916 following single dose administration
time frame: Cycle1 Day1 (pre-dose, end of infusion, 1, 3, 8, 24 hours post-infusion), Day8, Day15 (21-day cycle)
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.
measure: Part 2: Arm A: AUC (0 to inf) for GSK2857916 following single dose administration
time frame: Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (21-day cycle)
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.
measure: Part 2: Arm B: AUC (0 to inf) for GSK2857916 following single dose administration
time frame: Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (28-day cycle)
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.
measure: Part 1: Maximum observed plasma concentration (Cmax) for GSK2857916 following single dose administration
time frame: Cycle1 Day1 (pre-dose, end of infusion, 1, 3, 8, 24 hours post-infusion), Day8, Day15 (21-day cycle)
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.
measure: Part 2: Arm A: Cmax for GSK2857916 following single dose administration
time frame: Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (21-day cycle)
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.
measure: Part 2: Arm B: Cmax for GSK2857916 following single dose administration
time frame: Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (28-day cycle)
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.
measure: Part 1: Time to Cmax (Tmax) for GSK2857916 following single dose administration
time frame: Cycle1 Day1 (pre-dose, end of infusion, 1, 3, 8, 24 hours post-infusion), Day8, Day15 (21-day cycle)
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.
measure: Part 2: Arm A: Tmax for GSK2857916 following single dose administration
time frame: Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (21-day cycle)
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.
measure: Part 2: Arm B: Tmax for GSK2857916 following single dose administration
time frame: Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (28-day cycle)
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.
measure: Part 1: Systemic clearance (CL) for GSK2857916 following single dose administration
time frame: Cycle1 Day1 (pre-dose, end of infusion, 1, 3, 8, 24 hours post-infusion), Day8, Day15 (21-day cycle)
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.
measure: Part 2: Arm A: CL for GSK2857916 following single dose administration
time frame: Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (21-day cycle)
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.
measure: Part 2: Arm B: CL for GSK2857916 following single dose administration
time frame: Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (28-day cycle)
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.
measure: Part 1: Volume of distribution at steady state (Vss) for GSK2857916 following single dose administration
time frame: Cycle1 Day1 (pre-dose, end of infusion, 1, 3, 8, 24 hours post-infusion), Day8, Day15 (21-day cycle)
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.
measure: Part 2: Arm A: Vss for GSK2857916 following single dose administration
time frame: Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (21-day cycle)
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.
measure: Part 2: Arm B: Vss for GSK2857916 following single dose administration
time frame: Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (28-day cycle)
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.
measure: Part 1: Terminal phase half-life (T1/2) for GSK2857916 following single dose administration
time frame: Cycle1 Day1 (pre-dose, end of infusion, 1, 3, 8, 24 hours post-infusion), Day8, Day15 (21-day cycle)
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.
measure: Part 2: Arm A: T1/2 for GSK2857916 following single dose administration
time frame: Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (21-day cycle)
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.
measure: Part 2: Arm B: T1/2 for GSK2857916 following single dose administration
time frame: Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (28-day cycle)
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.
measure: Part 1: Concentration at the end of infusion of GSK2857916 following repeat dose administration
time frame: Cycle1 Day1 (pre-dose, end of infusion, 1, 3, 8, 24 hours post-infusion), Day8, Day15; Cycle 2 Day1, Cycle 3 Day1, Cycle 6 Day1, Cycle9 Day1, and Cycle12 Day1 (pre-dose, end of infusion); Cycle 16 Day1 (pre-dose) (21-day cycle)
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.
measure: Part 2: Arm A: Concentration at the end of infusion of GSK2857916 following repeat dose administration
time frame: Up to approximately 2.2 years
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.
measure: Part 2: Arm B: Concentration at the end of infusion of GSK2857916 following repeat dose administration
time frame: Up to approximately 2.2 years
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.
measure: Part 1: Trough plasma concentration (Ctrough) for GSK2857916 following repeat dose administration
time frame: Cycle1 Day1 (pre-dose, end of infusion, 1, 3, 8, 24 hours post-infusion), Day8, Day15; Cycle 2 Day1, Cycle 3 Day1, Cycle 6 Day1, Cycle9 Day1, and Cycle12 Day1 (pre-dose, end of infusion); Cycle 16 Day1 (pre-dose) (21-day cycle)
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.
measure: Part 2: Arm A: Ctrough for GSK2857916 following repeat dose administration
time frame: Up to approximately 2.2 years
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.
measure: Part 2: Arm B: Ctrough for GSK2857916 following repeat dose administration
time frame: Up to approximately 2.2 years
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.
measure: Part 1: Observed accumulation ratio for GSK2857916 following repeat dose administration
time frame: Cycle1 Day1 (pre-dose, end of infusion, 1, 3, 8, 24 hours post-infusion), Day8, Day15; Cycle 2 Day1, Cycle 3 Day1, Cycle 6 Day1, Cycle9 Day1, and Cycle12 Day1 (pre-dose, end of infusion); Cycle 16 Day1 (pre-dose) (21-day cycle)
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.
measure: Part 2: Arm A: Observed accumulation ratio for GSK2857916 following repeat dose administration
time frame: Up to approximately 2.2 years
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.
measure: Part 2: Arm B: Observed accumulation ratio for GSK2857916 following repeat dose administration
time frame: Up to approximately 2.2 years
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of GSK2857916.
measure: Part 1: AUC (0 to t) for Cysteine maleimidocaproyl monomethyl auristatin F (cys-mcMMAF) following single dose administration
time frame: Cycle1 Day1 (pre-dose, end of infusion, 1, 3, 8, 24 hours post-infusion), Day8, Day15 (21-day cycle)
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.
measure: Part 2: Arm A: AUC (0 to t) for cys-mcMMAF following single dose administration
time frame: Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (21-day cycle)
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.
measure: Part 2: Arm B: AUC (0 to t) for cys-mcMMAF following single dose administration
time frame: Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (28-day cycle)
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.
measure: Part 1: AUC (0 to tau) for cys-mcMMAF following single dose administration
time frame: Cycle1 Day1 (pre-dose, end of infusion, 1, 3, 8, 24 hours post-infusion), Day8, Day15 (21-day cycle)
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.
measure: Part 2: Arm A: AUC (0 to tau) for cys-mcMMAF following single dose administration
time frame: Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (21-day cycle)
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.
measure: Part 2: Arm B: AUC (0 to tau) for cys-mcMMAF following single dose administration
time frame: Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (28-day cycle)
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.
measure: Part 1: AUC (0 to inf) for cys-mcMMAF following single dose administration
time frame: Cycle1 Day1 (pre-dose, end of infusion, 1, 3, 8, 24 hours post-infusion), Day8, Day15 (21-day cycle)
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.
measure: Part 2: Arm A: AUC (0 to inf) for cys-mcMMAF following single dose administration
time frame: Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (21-day cycle)
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.
measure: Part 2: Arm B: AUC (0 to inf) for cys-mcMMAF following single dose administration
time frame: Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (28-day cycle)
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.
measure: Part 1: Cmax for cys-mcMMAF following single dose administration
time frame: Cycle1 Day1 (pre-dose, end of infusion, 1, 3, 8, 24 hours post-infusion), Day8, Day15 (21-day cycle)
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.
measure: Part 2: Arm A: Cmax for cys-mcMMAF following single dose administration
time frame: Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (21-day cycle)
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.
measure: Part 2: Arm B: Cmax for cys-mcMMAF following single dose administration
time frame: Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (28-day cycle)
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.
measure: Part 1: Tmax for cys-mcMMAF following single dose administration
time frame: Cycle1 Day1 (pre-dose, end of infusion, 1, 3, 8, 24 hours post-infusion), Day8, Day15 (21-day cycle)
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.
measure: Part 2: Arm A: Tmax for cys-mcMMAF following single dose administration
time frame: Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (21-day cycle)
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.
measure: Part 2: Arm B: Tmax for cys-mcMMAF following single dose administration
time frame: Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (28-day cycle)
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.
measure: Part 1: T1/2 for cys-mcMMAF following single dose administration
time frame: Cycle1 Day1 (pre-dose, end of infusion, 1, 3, 8, 24 hours post-infusion), Day8, Day15 (21-day cycle)
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.
measure: Part 2: Arm A: T1/2 for cys-mcMMAF following single dose administration
time frame: Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (21-day cycle)
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.
measure: Part 2: Arm B: T1/2 for cys-mcMMAF following single dose administration
time frame: Cycle1 Day1 (pre-dose, end of infusion, 2 hours after start of infusion, 24 hours after start of infusion); Cycle1 Day4; one sample between Cycle1 Day8 to Day15 (28-day cycle)
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.
measure: Part 1: Concentration at end of infusion for cys-mcMMAF following repeat dose administration
time frame: Cycle1 Day1 (pre-dose, end of infusion, 1, 3, 8, 24 hours post-infusion), Day8, Day15; Cycle 2 Day1, Cycle 3 Day1, Cycle 6 Day1, Cycle9 Day1, and Cycle12 Day1 (pre-dose, end of infusion); Cycle 16 Day1 (pre-dose) (21-day cycle)
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.
measure: Part 2: Arm A: Concentration at end of infusion for cys-mcMMAF following repeat dose administration
time frame: Up to approximately 2.2 years
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.
measure: Part 2: Arm B: Concentration at end of infusion for cys-mcMMAF following repeat dose administration
time frame: Up to approximately 2.2 years
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.
measure: Part 1: Ctrough for cys-mcMMAF following repeat dose administration
time frame: Cycle1 Day1 (pre-dose, end of infusion, 1, 3, 8, 24 hours post-infusion), Day8, Day15; Cycle 2 Day1, Cycle 3 Day1, Cycle 6 Day1, Cycle9 Day1, and Cycle12 Day1 (pre-dose, end of infusion); Cycle 16 Day1 (pre-dose) (21-day cycle)
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.
measure: Part 2: Arm A: Ctrough for cys-mcMMAF following repeat dose administration
time frame: Up to approximately 2.2 years
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.
measure: Part 2: Arm B: Ctrough for cys-mcMMAF following repeat dose administration
time frame: Up to approximately 2.2 years
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.
measure: Part 1: Observed accumulation ratio for cys-mcMMAF following repeat dose administration
time frame: Cycle1 Day1 (pre-dose, end of infusion, 1, 3, 8, 24 hours post-infusion), Day8, Day15; Cycle 2 Day1, Cycle 3 Day1, Cycle 6 Day1, Cycle9 Day1, and Cycle12 Day1 (pre-dose, end of infusion); Cycle 16 Day1 (pre-dose) (21-day cycle)
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.
measure: Part 2: Arm A: Observed accumulation ratio for cys-mcMMAF following repeat dose administration
time frame: Up to approximately 2.2 years
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.
measure: Part 2: Arm B: Observed accumulation ratio for cys-mcMMAF following repeat dose administration
time frame: Up to approximately 2.2 years
description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of cys-mcMMAF.
measure: Part 1 and Part 2: Number of participants who develop anti-drug antibodies (ADAs) against GSK2857916
time frame: Up to approximately 2.2 years
description: Serum samples will be collected for analysis of presence of anti-GSK2857916 antibodies by a validated electrochemiluminescent immunoassay.
measure: Part 1 and Part 2: Titers of anti-GSK2857916 antibodies
time frame: Up to approximately 2.2 years
description: Serum samples will be collected for analysis of presence of anti-GSK2857916 antibodies by a validated electrochemiluminescent immunoassay.
measure: Part 1 and Part 2: Overall response rate
time frame: Up to approximately 2.2 years
description: Overall response rate is defined as the percentage of participants with a confirmed partial response or better, according to the International Myeloma Working Group (IMWG) response criteria, as assessed by the investigator.
measure: Part 1 and Part 2: Clinical benefit rate
time frame: Up to approximately 2.2 years
description: Clinical benefit rate is defined as the percentage of participants with a confirmed minimal response (MR) or better, according to the IMWG response criteria, as assessed by the investigator.
arm group label: Part 1: Belantamab mafodotin Monotherapy
arm group type: Experimental
arm group label: Part 2: Arm A: Belantamab mafodotin+Bortezomib/Dexamethasone
arm group type: Experimental
arm group label: Part 2: Arm B: Belantamab mafodotin+Pomalidomide/Dexamethasone
arm group type: Experimental
intervention type: Drug
intervention name: Belantamab mafodotin
description: Belantamab mafodotin will be administered as an intravenous infusion.
arm group label: Part 1: Belantamab mafodotin Monotherapy
arm group label: Part 2: Arm A: Belantamab mafodotin+Bortezomib/Dexamethasone
arm group label: Part 2: Arm B: Belantamab mafodotin+Pomalidomide/Dexamethasone
intervention type: Drug
intervention name: Bortezomib
description: Bortezomib solution for injection will be administered subcutaneously.
arm group label: Part 2: Arm A: Belantamab mafodotin+Bortezomib/Dexamethasone
intervention type: Drug
intervention name: Dexamethasone
description: Dexamethasone tablets will be administered orally.
arm group label: Part 2: Arm A: Belantamab mafodotin+Bortezomib/Dexamethasone
arm group label: Part 2: Arm B: Belantamab mafodotin+Pomalidomide/Dexamethasone
intervention type: Drug
intervention name: Pomalidomide
description: Pomalidomide capsules will be administered orally.
arm group label: Part 2: Arm B: Belantamab mafodotin+Pomalidomide/Dexamethasone
criteria: 
gender: All
minimum age: 20 Years
maximum age: N/A
healthy volunteers: No
last name: GSK Clinical Trials
role: Study Director
affiliation: GlaxoSmithKline
facility: 
facility: 
facility: 
facility: 
country: Japan
responsible party type: Sponsor
mesh term: Multiple Myeloma
mesh term: Neoplasms, Plasma Cell
mesh term: Dexamethasone
mesh term: Bortezomib
mesh term: Pomalidomide
sharing ipd: Yes
ipd description: IPD for this study will be made available via the Clinical Study Data Request site.
ipd info type: Study Protocol
ipd info type: Statistical Analysis Plan (SAP)
ipd info type: Informed Consent Form (ICF)
ipd info type: Clinical Study Report (CSR)
ipd time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
ipd access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
ipd url: http://clinicalstudydatarequest.com